Azenta, Inc. (AZTA) Appoints Dipal Doshi to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
Azenta Announces the Election of Dipal Doshi to its Board of Directors
January 30, 2025 4:05 PM ESTBURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of... More
